FOLH1 and cancer: The cytotoxicities of PSMA-activated prodrug CPT-HT-J-ZLn and PSMA hydrolysate CPT-D-GLn were evaluated by MTT assays on PSMA-expressing (PSMA+) cancer cell LNCaP-FGC, non-PSMA-expressing (PSMA−) cancer cells HepG2, MCF-7, Hela, DU145, and PC-3, and normal cells MDCK, LO2, respectively, using CPT as a positive control.